Study #2022-1054
A phase II, randomized, multicenter, open-label, controlled study of RO7247669 alone or in combination with Tiragolumab versus Atezolizumab in patients with previously untreated locally advanced or metastatic Urothelial Bladder cancer who are ineligible for Platinum-Containing chemotherapy.
MD Anderson Study Status
Not Accepting
Treatment Agent
Atezolizumab, Tobemstomig, Tiragolumab
Description
This study will evaluate the safety of tobemstomig alone or in combination with tiragolumab compared with atezolizumab in participants with previously untreated, locally advanced or metastatic urothelial cancer (mUC) who are ineligible to receive a platinum containing chemotherapy.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Urothelial Cancer
Study phase:
Phase II
Physician name:
Omar Alhalabi
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-982-0789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.